osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
now with the third presentation of the plenary session with the #adaura study. now with an overall survival benefit with osimertinib in patients with egfr+ nsclc. #asco23 
PGY-2 @BrighamMedRes | @USJLiban MSc '16 MD '18 | @DanaFarber Research '21 | @ASCO #IMG CoP & #JCOCCI Editorial Board | Cancer Genomics |
FCOI: https://t.co/dYsEwGGqP1